OCTA in Cardiovascular Disease and Healthy Controls
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of Erlangen-Nürnberg Medical School
About this trial
This prospective clinical study will involve the non-invasive assessment of retinal vessels using OCTA (Cirrus OCT 6000 AngioPlex) and scanning laser Doppler flowmetry (SLDF) in patients with cardiovascular disease and healthy individuals. The study will be conducted at the Clinical Research Centre (CRC), Department of Nephrology and Hypertension at the University of Erlangen-Nuremberg.
Eligibility criteria
Qualifiers
cardiovascular disease defined as one or more of the following: arterial hypertension, type 2 diabetes mellitus, chronic kidney disease, heart failure
BMI 18-29.9 kg/m2
Non-smoker
Good general health, as determined by study personnel based on assessments of previous visits, including anamnesis, vital signs, physical examination and clinical laboratory parameters.
Disqualifiers
Active ophthalmological (retinal) disease resulting in impaired visual assessment of retinal vessels (e.g. glaucoma, cataracts, retinal oedema).
Active ophthalmological (retinal) disease with reduced visual assessment of retinal vessels (e.g. glaucoma, cataracts, retinal oedema).
clinically relevant deviation in physical examination, vital signs, or laboratory parameters (based on the physician's clinical judgement).
a clinically relevant history of cardiovascular disease or any other previously known cardiovascular disease
Trial design
Treatments tested in this trial
- Retinal vascular assessment using OCTA and SLDF
Treatment groups
64 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Erlangen-Nürnberg Medical School
Lead sponsor
German Diabetes Association
Collaborator
Source ClinicalTrials.gov